Abstracts Archive - Page 933 of 2425 - ACR Meeting Abstracts

Abstract Number: 2620 • 2019 ACR/ARP Annual Meeting
Effects of Tofacitinib Suppressed Pulmonary Vascular Remodeling of Allergic Vasculitis in a Murine Model
Yuka Oikawa¹, Kohei Yamauchi ² and Makoto Maemondo ¹, ¹Iwate Medical University School of Medicine, Morioka, Japan, Division of Pulmonary medicine, Allergy and Rheumatology, Department of Internal Medicine, morioka, Japan, ²Takizawa central Hospital, morioka, Japan
Background/Purpose: We reported allergic granulomatous vasculitis with eosinophil infiltration in an asthma model of C57BL/6 sensitized with ovalbumin (OVA). TGF-btea and IL-6 are thought to…
Abstract Number: 2621 • 2019 ACR/ARP Annual Meeting
Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis
Linda Vergel Orduz¹, Alejandro Brigante ², Diego Marino ³, Natalia Perrotta ³, Romina Hassan ⁴, Gisele Verna ⁵, Adriana Hamaui ⁶, Eduardo Kerzberg ⁷ and Diana Dubinsky ⁶, ¹Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, ²Sanatorio Güemes, Servicio de Medicina Interna – Reumatología, Francisco Acuña de Figueroa 1240, C1180AAD, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ³Hospital de Clínicas José de San Martín, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Hospital Ramos Mejía, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁶Sanatorio Güemes, Buenos Aires, Argentina, ⁷Hospital Ramos Mejia, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: In associated ANCA vasculitis (AAV), rapidly progressive glomerulonephritis (GN) is one of the most serious complications. In 40% of cases they progress to chronic…
Abstract Number: 2622 • 2019 ACR/ARP Annual Meeting
A Single Center Retrospective Analysis of Efficacy and Safety Between Low-Dose versus High-Dose Rituximab as Remission Induction Therapy with ANCA-Associated Vasculitis
Kei Hirose¹, Manami Hirata ¹, Akiko Ueno ¹ and Masahiro Yamamura ¹, ¹Okayama Saiseikai General Hospital, Okayama City, Japan
Background/Purpose: Rituximab therapy for ANCA-associated vasculitis (AAV) patients was covered by insurance from 2013 in Japan. Administration of four once-weekly doses of 375 mg/m2 rituximab…
Abstract Number: 2623 • 2019 ACR/ARP Annual Meeting
Abnormality of Percentages and Absolute Numbers of CD4+ Memory and Regulatory T Subset Cells in ANCA-associated Vasculitis
Yanlin Wang¹, Xiangcong Zhao ², Chong Gao ³ and Jing Luo ², ¹The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), ²the Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ³Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: CD4+ T cell subsets control immune system in check and prevent autoimmunity by keeping a balance among them. However, their levels of blood in ANCA-associated vasculitis (AAV), especially absolute…
Abstract Number: 2624 • 2019 ACR/ARP Annual Meeting
Comparison Between Long-Term and Conventional Rituximab-Maintenance Treatments: Results of a Placebo-Controlled Randomized Trial
Pierre Charles¹, Elodie Perrodeau ², Maxime Samson ³, Bernard Bonnotte ⁴, Mohamed Hamidou ⁵, Christian Agard ⁵, Antoine Huart ⁶, Alexandre Karras ⁷, François Lifermann ⁸, Pascal Godmer ⁹, Pascal Cohen ¹⁰, Catherine Hanrotel-Saliou ¹¹, Nicolas Martin-Silva ¹², Grégory Pugnet ¹³, François Maurier ¹⁴, Jean Sibilia ¹⁵, Pierre-Louis Carron ¹⁶, Pierre Gobert ¹⁷, Nadine Meaux Ruault ¹⁸, Thomas Le Gallou ¹⁹, Stéphane Vinzio ²⁰, Jean-François Viallard ²¹, Eric Hachulla ²², Christine Vinter ², Xavier Puéchal for the French Vasculitis Study Group ¹⁰, Benjamin Terrier ¹⁰, Philippe Ravaud ², Luc Mouthon ¹⁰ and Loic Guillevin ¹⁰, ¹Institut Mutualiste Montsouris, Paris, France, ²APHP, Paris, France, ³CHU Dijon, Dijon, France, ⁴Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ⁵CHU Nantes, Nantes, France, ⁶CHU Toulouse, Toulouse, France, ⁷Paris HEGP, Paris, France, ⁸CH Dax, Dax, France, ⁹CH Bretagne-Atlantique, Vannes, France, ¹⁰National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ¹¹CHU Brest, Brest, France, ¹²CHU Caen, Caen, France, ¹³CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, ¹⁴Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ¹⁵CHU Strasbourg, Strasbourg, France, ¹⁶Grenoble, Grenoble, France, ¹⁷CH Avignon, Avignon, France, ¹⁸CHU Besançon, Besançon, France, ¹⁹CHU Rennes, Rennes, France, ²⁰GHM Grenoble, Grenoble, France, ²¹CHU Bordeaux, Bordeaux, France, ²²Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: MAINRITSAN-trial results1 demonstrated rituximab superiority (500 mg on days 0 and 14, then at months 6, 12 and 18) to azathioprine to maintain remission…
Abstract Number: 2625 • 2019 ACR/ARP Annual Meeting
Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement
Gelsomina Alle¹, John Jaramillo Gallego ², Marina Scolnik ³, Valeria Scaglioni ², Martin Brom ⁴, Carlos Varela ⁵, Gustavo Greloni ⁵ and Enrique Soriano ⁶, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Nephrology Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The aim of this study was to evaluate the predictors of advanced chronic kidney disease (ACKD) in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis…
Abstract Number: 2626 • 2019 ACR/ARP Annual Meeting
Cell-free Mitochondrial DNA Levels in Granulomatosis with Polyangiitis
Lindsay Lally¹, Sebastian E. Sattui ², Jackie Finik ³, Augustine Choi ⁴, Rennie Rhee ⁵, Peter Merkel ⁶, W. Joseph McCune ⁷, E William St. Clair ⁸, Ulrich Specks ⁹, John Stone ¹⁰ and Robert Spiera ¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery, New York, NY, New York, NY, ⁴Weill Cornell Medicine, New York, ⁵University of Pennsylvania, Division of Rheumatology, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Michigan, Ann Arbor, MI, ⁸Duke, Raleigh, ⁹Mayo Clinic College of Medicine, Rochester, MN, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Circulating cell-free mitochondrial DNA (mtDNA) is released during non-apoptotic processes such as NETosis. Increased levels of mtDNA are associated with autophagic dysfunction and inflammasome…
Abstract Number: 2627 • 2019 ACR/ARP Annual Meeting
Association of Work Productivity Assessed by Absenteeism and Presenteeism with Disease Activity, Damage and Health-related Quality of Life in Patients with ANCA-associated Vasculitis
Shinya Hirahara¹, Yasuhiro Katsumata ¹, Ken-ei Sada ², Hiroko Nagafuchi ³, Eiichi Tanaka ¹ and Masayoshi Harigai ¹, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kitaku, Okayama, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan
Background/Purpose: Chronic inflammatory diseases such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) substantially affects patients’ daily lives, including their ability to work. Although the management…
Abstract Number: 2628 • 2019 ACR/ARP Annual Meeting
Mortality Predictors in ANCA-associated Vasculitis: Experience of a Brazilian Monocentric Cohort of a Rheumatology Center
Marilia Dagostin¹, Sergio Nunes ², Samuel Shinjo ³ and Rosa Pereira ⁴, ¹University of Sao Paulo, São Paulo, Brazil, ²Univeristy Of Sao Paulo, São Paulo, ³Univeristy Of Sao Paulo, São Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Mortality of patients with ANCA-associated vasculitis (AAV) is higher than the general population. There are few papers in the literature regarding the factors associated…
Abstract Number: 2629 • 2019 ACR/ARP Annual Meeting
Urinary Inflammatory Cell Analysis Reflects the Renal Histopathology in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Yoko Wada¹, Masanori Sudo ², Takeshi Kuroda ³, Masaaki Nakano ⁴ and Ichiei Narita ², ¹Niigata Rinko Hospital, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ³Health administration office, Niigata University, Niigata, Niigata, Japan, ⁴School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Niigata, Japan
Background/Purpose: The anti-neutrophil cytoplasmic autoantibody (ANCA)- associated vasculitides (AAVs) include microscopic polyangiitis (MPA), granulomatosis with polyangitis (GPA), and eosinophilic granulomatosis with polyangitis (EGPA). These small-vessel…
Abstract Number: 2630 • 2019 ACR/ARP Annual Meeting
A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis
Ebru Dirikgil¹, Peter Verhoeven ², Sander Tas ³, Abraham Rutgers ⁴, Hein Bernelot Moens ⁵, Jacob van Laar ⁶, Willem Jan Bos ⁷ and Onno Teng ¹, ¹LUMC, Leiden, Netherlands, ²The Dutch Vasculitis Foundation, Silvolde, Netherlands, ³Amsterdam Rheumatology & immunology Center, Amsterdam UMC/University of Amsterdam, Amsterdam, Netherlands, ⁴University Medical Center Groningen, Groningen, Netherlands, ⁵Ziekenhuisgroep Twente, Almelo, Netherlands, ⁶UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁷St. Antoniusziekenhuis, Nieuwegein, Netherlands
Background/Purpose: Several guidelines have been published on the diagnosis and treatment of anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV). These guidelines provide an evidence-based approach…
Abstract Number: 2631 • 2019 ACR/ARP Annual Meeting
Increased Risk of Acute Coronary Artery Disease and Ischemic Stroke in Patients with Eosinophilic Granulomatosis with Polyangiitis
Morgane Mourguet ¹, Dominique Chauveau ², Stan Faguer ², JB Ruidavets ², Yannick Béjot ³, Grégoire Prevot ⁴, Olivier Lairez ², David Ribes ², Antoine Huart ², Laurent Alric ², Leo Astudillo ¹, Laurent Sailler ¹ and Grégory Pugnet⁵, ¹CHU Purpan, Toulouse, France, ²CHU Rangueil, Toulouse, France, ³CHU Dijon, Dijon, France, ⁴CHU Larrey, Toulouse, France, ⁵CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France
Background/Purpose: Current treatment approaches have greatly improved the survival of eosinophilic granulomatosis with Polyangiitis (EGPA) patients, however both morbidity andmortality are still significant mainly due…
Abstract Number: 2632 • 2019 ACR/ARP Annual Meeting
Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center
Sana Afroz¹ and Najia Shakoor ², ¹RUMC, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: For years, cyclophosphamide (CYC) has been the primary treatment for severe anca-associated vasculitides (AAV) and has significantly improved disease related mortality. In addition, maintenance…
Abstract Number: 2633 • 2019 ACR/ARP Annual Meeting
Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis
Audrey Hopkins¹, Stanley Chu ², Philip Seo ³, Eric Gapud ¹, Brendan Antiochos ¹, Shaker Eid ¹, Jason Liebowitz ¹ and Duvuru Geetha ¹, ¹Johns Hopkins Bayview Medical Center, Baltimore, ²Johns Hopkins University, Baltimore, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Induction regimens using either cyclophosphamide (CYC) or rituximab (RTX) have been shown to have similar efficacy and similar rates of adverse events in randomized…
Abstract Number: 2634 • 2019 ACR/ARP Annual Meeting
ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients
Laura van Dam¹, Ebru Dirikgil ², Edwin Bredewold ², Argho Ray ², Ton Rabelink ², Cees van Kooten ² and Onno Teng ², ¹LUMC, Leiden, Zuid-Holland, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Recent studies have demonstrated that in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with successful remission-induction (RI) after cyclophosphamide (CYC), maintenance treatment with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].